Autolus Therapeutics (NASDAQ:AUTL) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Autolus Therapeutics (NASDAQ:AUTL) released its quarterly earnings data on Friday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.07), FiscalAI reports. Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 63.76%. The company had revenue of $24.29 million for the quarter, compared to the consensus estimate of $23.92 million.

Here are the key takeaways from Autolus Therapeutics’ conference call:

• Commercial launch momentum: AUCATZYL generated $74.3M revenue in 2025, the company reiterated 2026 guidance of $120M–$135M, expects to reach positive gross margin in 2026, and targets >80 activated centers by year-end.
• Strong real‑world Obe‑cel outcomes: ROCCA consortium data (91 infused patients) showed ~92% CR at day 28 and a safety profile consistent with clinical trials (no real‑world grade ≥3 CRS and low high‑grade ICANS), supporting physician adoption.
• Cash runway narrowed — cash, equivalents and marketable securities were $300.7M at year‑end 2025 (down from $588M), and management expects runway into Q4 2027, implying potential future financing needs if milestones or uptake miss expectations.
• Pipeline catalysts and timelines — pivotal pediatric CATULUS data expected by end of 2027, LUMINA (lupus nephritis) readout in 2028, BOBCAT (progressive MS) early data this year with full phase I in 2027, and ALARIC (AL amyloidosis) early data planned in 2026.
• Accounting and revenue recognition change — the company refined revenue/cost accounting to recognize AUCATZYL sales and associated COGS upon confirmation of second‑dose administration (no material impact on full‑year revenue but changes timing of recognition).

Autolus Therapeutics Stock Down 6.2%

Autolus Therapeutics stock opened at $1.21 on Friday. The company’s 50-day moving average price is $1.49 and its 200-day moving average price is $1.52. The company has a market cap of $322.03 million, a PE ratio of -1.12 and a beta of 1.95. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $2.70.

Key Headlines Impacting Autolus Therapeutics

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Company reiterated 2026 guidance: management expects AUCATZYL® net product revenue of $120–$135M and a shift to positive gross margin in 2026 — a clear path to improving unit economics and cash-generation visibility. Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
• Positive Sentiment: Commercial traction: AUCATZYL reported ~$23.3M net product revenue in Q4 and $74.3M for FY2025; UK launch underway after positive NICE evaluation and real‑world data show favorable activity/safety — supports revenue ramp thesis. Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst upgrades/price target upside: Needham reaffirmed a Buy with a $10 PT (large theoretical upside from current levels) and Truist upgraded to Strong-Buy — these notes can attract speculative buying ahead of clinical readouts. Benzinga
• Neutral Sentiment: Pipeline catalyst timeline: pivotal Phase 2 trials enrolling in lupus nephritis and pediatric ALL; initial BOBCAT Phase 1 data in progressive MS expected late 2026 — potential upside but not immediate. Press Release
• Neutral Sentiment: Company hosted an earnings call and published the transcript/slides — useful for detail on margin assumptions and cash runway into Q4 2027. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Earnings miss and weak profitability metrics: Q4 EPS of ($0.34) missed consensus ($0.27); company still deeply unprofitable with a large negative net margin and negative ROE — these metrics pressure sentiment in the near term. Press Release / Slide Deck
• Negative Sentiment: Analyst caution: Some outlets (and at least one analyst note) highlight a challenging risk/reward despite strong B-ALL data, citing reliance on upcoming autoimmune and pediatric data to re‑rate the stock. Seeking Alpha Hold-perspective

Analysts Set New Price Targets

A number of brokerages have issued reports on AUTL. HC Wainwright initiated coverage on shares of Autolus Therapeutics in a report on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. Zacks Research raised Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. Finally, Truist Financial upgraded Autolus Therapeutics to a “strong-buy” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marex Group plc bought a new stake in Autolus Therapeutics during the second quarter worth approximately $28,000. SmartHarvest Portfolios LLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $43,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Autolus Therapeutics in the 3rd quarter worth approximately $46,000. Invesco Ltd. boosted its holdings in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after purchasing an additional 11,381 shares during the period. Finally, Federation des caisses Desjardins du Quebec bought a new position in shares of Autolus Therapeutics during the 4th quarter valued at approximately $62,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.